You are here


Get to know Robert Fabregat, new CEO of Biocat

This year of Biocat’s 15th anniversary brought a passing of the baton at the helm of the organization to Robert Fabregat. Learn more about his first months, the areas he wants to strengthen, how he imagines the BioRegion a few years from now, and his healthy habits


Covid-19 pandemic has boosted cutting-edge research and innovation, reaching a record investment for companies in the BioRegion 

6 ‘made in Catalonia’ Covid-19 prediction and prognosis methods

Predicting and establishing the prognosis of diseases is key to controlling them. Biocat will provide support for the 19 research projects in the BioRegion awarded €4 million from the Catalan Ministry of Health to research the pandemic, 6 of which are looking into possible prediction or prognosis methods for this disease. Let’s look at how the centers are focusing their research.

3 Catalan Covid-19 vaccines

A few days ago, the 19 research projects in the BioRegion awarded €4 million from the Catalan Ministry of Health to research the pandemic, with technical support from Biocat, were announced. Of these projects, 3 are researching potential vaccines for the SARS-CoV-2 virus. Let’s look at the preventive strategies they propose.

5 existing drugs that could be used for Covid-19

Five research projects in the BioRegion of Catalonia are investigating how to take advantage of therapies already in use for other diseases to treat Covid-19. They have received funding from the Catalan Ministry of Health to study this new path towards a possible cure to the pandemic. Let’s look at what they’re working on.


Advances in Covid-19 research and devices mark the news in the BioRegion in April

Will Covid-19 affect investment in the biomedical sector?

The BioRegion of Catalonia has a solid local investment fabric and the number of international investors has grown tenfold over the past 5 years. How will the pandemic affect their activity? Companies are seeing some operations postponed, but investors, for now, are optimistic: activity won’t stop, quite the opposite, this will boost interest to attract more investment.


Companies and research stakeholders in the healthcare, food, chemistry, energy, industrial systems and mobility sectors can sign up

Clara Campàs (Asabys Partners): “Society’s growing interest in science due to Covid-19 could boost investment in healthcare”

Clara Campàs, partner and co-founder of specialized venture capital fund Asabys Partners, analyzes how the global Covid-19 crisis is affecting the sector and is optimistic about the future of investment in healthcare.

Joël Jean-Mairet (Ysios Capital): “The Covid-19 crisis has to remind us of the need to innovate in the life sciences”

Joël Jean-Mairet, managing partner of Ysios Capital, explained how he sees this crisis from the perspective of a venture capital fund and warns that continued investment in healthcare innovation is more necessary than ever.